Clinical trial
The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize…
NCT00302211 · Actelion, Industry · Terminated
Key facts
| NCT number | NCT00302211 |
|---|---|
| Title | The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension |
| Official title | A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of Inhaled Iloprost in Patients With Pulmonary Arterial Hypertension Receiving Oral Sildenafil |
| Acronym | VISION |
| Lead sponsor | Actelion, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pulmonary Hypertension |
| Intervention type | Drug |
| Interventions | Inhaled Iloprost (5 μg), Inhaled Placebo, Sildenafil, Bosentan |
| Enrollment | 67 |
| Start date | Feb 1, 2006 |
| Primary completion | Dec 1, 2007 |
| Completion | Jul 1, 2008 |
| First posted | Mar 14, 2006 |
| Last update posted | Feb 4, 2025 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: